Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, remains one of the most difficult malignant diseases to treat. Its symptoms are often vague or delayed, and many people are diagnosed only after the disease has spread beyond the pancreas. Although chemotherapy can slow progression and relieve symptoms, its benefits are frequently limited and may be accompanied by substantial toxicity.
For more than four decades, the RAS family of proteins—especially KRAS—has been recognised as a central driver of PDAC. In healthy cells, RAS acts like a tightly regulated molecular switch, transmitting growth signals only when they are needed. In pancreatic cancer, however, mutations can leave this switch permanently activated, encouraging relentless cell division.
For a long time, RAS was considered “undruggable”. Its surface appeared to lack the deep binding pockets that conventional small-molecule medicines typically use. Daraxonrasib, also known as RMC-6236, represents a different therapeutic strategy: rather than attempting to block RAS through a conventional direct interaction, it is designed to inhibit active RAS signalling through a molecular complex involving cyclophilin A, a naturally abundant cellular protein.
A Molecular-Glue Strategy: Daraxonrasib is a macrocyclic compound, meaning that its chemical structure forms a large ring. Its mechanism is notable not because it attacks RAS in isolation, but because it uses cyclophilin A as part of the therapeutic interaction.
The drug first binds cyclophilin A. This binary complex can then engage active RAS—RAS in its ON state—to form a stable tricomplex. By occupying a strategic surface on active RAS, this complex interferes with the protein’s ability to interact with downstream signalling partners that promote tumour growth.
This approach is clinically important because it is designed to inhibit several oncogenic RAS variants rather than one narrowly defined mutation. In pancreatic cancer, common KRAS alterations include G12D, G12V and G12R. The ability to address several variants could make this strategy relevant to a substantial proportion of patients with PDAC.
Why Molecular Profiling Matters: Every pancreatic tumour has its own molecular identity. In modern oncology, treating all patients with the same regimen without examining the tumour’s biology is increasingly difficult to justify. Comprehensive molecular profiling—usually performed with next-generation sequencing, or NGS—helps identify mutations and other genomic alterations that may influence prognosis, treatment selection, or eligibility for clinical trials.
This is particularly relevant in PDAC because most tumours contain an alteration involving KRAS or another RAS-family gene, but individual variants may differ in biological behaviour and therapeutic susceptibility. Molecular testing can also identify the smaller group of tumours that are RAS wild type, meaning that no RAS mutation has been detected.
In RAS wild-type PDAC, sequencing may uncover other therapeutically relevant changes, including gene fusions, DNA-repair defects, or biomarkers associated with sensitivity to targeted therapies, platinum-based chemotherapy, or immunotherapy in selected circumstances. Liquid biopsy—the analysis of circulating tumour DNA, or ctDNA, in a blood sample—may complement tissue testing by detecting tumour-derived genetic material and helping monitor molecular changes over time.
Early Clinical Evidence: Before the phase III study, daraxonrasib was evaluated in phase I/II clinical research involving patients with advanced PDAC who had previously received standard systemic treatment. These earlier data supported continued clinical development and helped establish an oral dose of 300 mg once daily for later studies.
In the phase I/II setting, approximately 30% of previously treated patients achieved an objective response, meaning measurable tumour shrinkage on imaging, while disease control was reported in about 90%. Median progression-free survival was approximately 8 months, although such early-stage findings should be interpreted cautiously because phase I/II trials are generally smaller and are not designed to provide definitive comparisons with standard treatment.
| Parameter in phase I/II research | Reported result | Plain-language meaning |
|---|---|---|
| Objective response rate | Approximately 30% | Measurable tumour shrinkage in some previously treated patients |
| Disease control rate | Approximately 90% | Tumour shrinkage or stabilisation in most participants |
| Median duration of response | 8.2 months | Typical time during which a response was maintained |
| Median progression-free survival | Approximately 8.1–8.5 months | Typical time before disease progression or death |
| Median overall survival | Approximately 13.1–15.6 months | Typical survival duration from treatment initiation in the studied population |
These results were encouraging, but they did not establish clinical superiority over chemotherapy. That question was addressed in the subsequent phase III RASolute 302 trial.
The RASolute 302 Trial: The international phase III RASolute 302 trial compared oral daraxonrasib, given at 300 mg once daily, with standard intravenous chemotherapy in patients with metastatic PDAC whose disease had progressed after prior treatment. The trial was randomised, meaning that participants were assigned by chance to receive daraxonrasib or chemotherapy in order to reduce bias.
At the 2026 annual meeting of the American Society of Clinical Oncology, investigators reported that daraxonrasib improved both overall survival and progression-free survival compared with chemotherapy. In the population with RAS G12 mutations, median overall survival was 13.2 months with daraxonrasib and 6.6 months with chemotherapy; the reported hazard ratio for death was 0.40, corresponding to a 60% relative reduction in the risk of death during the study period.
Median progression-free survival, assessed by blinded independent central review, was 7.3 months with daraxonrasib versus 3.5 months with chemotherapy. The reported objective response rates were 33.2% and 11.8%, respectively.[letswinpc]
| Outcome in RASolute 302 | Daraxonrasib | Chemotherapy |
|---|---|---|
| Median overall survival | 13.2 months | 6.6 months |
| Median progression-free survival | 7.3 months | 3.5 months |
| Objective response rate | 33.2% | 11.8% |
| Relative reduction in risk of death | 60% | Reference group |
| Twelve-month overall survival rate | 53.3% | 18.7% |
The magnitude of these results is clinically striking, particularly in a disease where therapeutic progress has historically been difficult. Even so, survival estimates may evolve with longer follow-up, and clinical decisions should be based on the full peer-reviewed publication, regulatory labelling where applicable, and discussion within an experienced multidisciplinary cancer team.
Symptoms and Quality of Life: In pancreatic cancer, treatment outcomes cannot be judged solely by tumour measurements or survival curves. Pain, fatigue, appetite loss, weight loss, digestive symptoms and time spent receiving medical care can profoundly affect daily life.
RASolute 302 also reported delays in deterioration of cancer-related pain, global health status and overall quality of life among patients treated with daraxonrasib compared with chemotherapy. This is especially relevant because an oral treatment can reduce the practical burden associated with repeated intravenous chemotherapy visits, although patients still require close monitoring and specialist follow-up.[ir.revmed]
More time is meaningful only if it is accompanied, as far as possible, by better symptom control, preserved independence and time with family and friends.
Safety and Tolerability: Daraxonrasib is not free of adverse effects. Because RAS signalling also has roles in healthy tissues, treatment can affect the skin, mouth and digestive system.
The most frequent adverse reaction is an inflammatory skin rash. Stomatitis—painful inflammation or ulceration of the mouth—can also occur, as can diarrhoea and nausea. These effects may require dose modifications, skin care, oral rinses, dietary adjustment and prompt medical evaluation.
| Grade 3 or higher adverse event | Daraxonrasib | Chemotherapy | Practical implication |
|---|---|---|---|
| Overall serious adverse events | 43.6% | 57.5% | Lower overall rate reported with daraxonrasib |
| Severe skin rash | 14.0% | Rare | Requires early dermatological supportive care |
| Severe stomatitis | 12.0% | Low incidence | Requires preventive oral care and targeted treatment |
| Discontinuation due to toxicity | 1.2% | 11.2% | Suggests greater treatment tolerability in the study population |
The lower rate of treatment discontinuation with daraxonrasib does not mean that adverse effects are minor or should be ignored. A rash or mouth inflammation can become clinically significant if not addressed early; patients should promptly report new symptoms to their oncology team.
Earlier Treatment Settings: Research is also exploring daraxonrasib in the first-line treatment of metastatic PDAC, including as monotherapy and in combination with gemcitabine plus nab-paclitaxel. Preliminary results presented at the 2026 meeting of the American Association for Cancer Research suggested high disease-control rates in small groups of previously untreated patients.
In an early cohort of 40 patients receiving daraxonrasib alone, the objective response rate was reported as 47%; in a similarly sized cohort receiving daraxonrasib with chemotherapy, it was 58%. Disease-control rates were 92% and 90%, respectively. These findings are promising but preliminary, and they cannot establish a first-line standard of care without larger comparative trials.
| First-line preliminary data | Daraxonrasib alone | Daraxonrasib plus chemotherapy |
|---|---|---|
| Number of patients | 40 | 40 |
| Objective response rate | 47% | 58% |
| Disease control rate | 92% | 90% |
| Estimated six-month progression-free survival | 71% | 84% |
| Estimated six-month overall survival | 83% | 90% |
| ctDNA reduction greater than 50% | 100% | 96% |
The reported early reduction in ctDNA is biologically encouraging. However, ctDNA remains an evolving clinical tool, and changes in circulating tumour DNA should not yet be interpreted as a definitive substitute for radiological assessment, symptoms and conventional clinical follow-up.
Resistance Remains Central: Cancer is an evolving biological system. Daraxonrasib is not a definitive cure, and tumours may eventually develop resistance through several mechanisms.
One potential route involves cyclophilin A itself. Because daraxonrasib relies on cyclophilin A to form the inhibitory tricomplex, tumour cells that alter or lose this protein may reduce the drug’s activity. Other resistance mechanisms may involve the activation of alternative survival pathways, including PI3K–AKT–mTORC1 signalling, or broader genomic changes that allow cancer cells to bypass RAS dependence.
Understanding these escape mechanisms is not merely an academic exercise. It may guide the design of next-generation RAS inhibitors, rational drug combinations and treatment strategies intended to delay or overcome resistance.
Access and Regulation: Daraxonrasib remains an investigational therapy in the United States. The FDA has granted it Breakthrough Therapy and Orphan Drug designations, and it has also issued a “safe to proceed” letter allowing Revolution Medicines to initiate an Expanded Access Program for eligible patients with previously treated metastatic PDAC.
Expanded access is not the same as full marketing approval. It is a regulated pathway that may permit access to an investigational medicine for eligible patients with serious or life-threatening disease when suitable alternatives are unavailable and participation in a clinical trial is not feasible. In the United States, requests under this protocol must be made by licensed physicians on behalf of eligible patients.[javierpenas]
Access outside the United States will depend on national regulations, the availability of clinical trials, local health-system decisions and, eventually, formal regulatory approvals and reimbursement policies.
Scope and Limits: Daraxonrasib represents a potentially important development in pancreatic-cancer research, but it must be understood with both hope and precision.
What It May Represent:
- A therapeutic strategy capable of inhibiting several common RAS G12 variants associated with pancreatic cancer.
- A major survival benefit over chemotherapy in the reported second-line phase III trial population.
- A possible improvement in patient-reported pain and quality-of-life outcomes compared with chemotherapy.
- An oral treatment option with a lower reported rate of discontinuation due to toxicity than the comparator chemotherapy regimen.
- A practical demonstration that multi-selective inhibition of active RAS can produce clinically meaningful results in metastatic PDAC.
What It Does Not Yet Represent:
- A cure for pancreatic cancer.
- A replacement for molecular testing, careful clinical assessment or multidisciplinary cancer care.
- A proven first-line standard of treatment; first-line evidence remains preliminary.
- A guarantee of durable benefit for every patient, since individual response and resistance mechanisms vary.
- A universally available therapy, as access, approval and cost may differ substantially among countries and healthcare systems.
A Change in Perspective: For decades, RAS was seen as one of cancer biology’s most difficult therapeutic targets. Daraxonrasib does not settle every question, and it does not remove the urgent need for earlier diagnosis, better supportive care, improved surgery and new combination treatments.
It does, however, strengthen a crucial idea that molecularly informed treatment can change the prospects of cancers that have long resisted therapeutic progress. The development of daraxonrasib is a reminder that basic science, patient participation in clinical trials and rigorous clinical research are not abstract pursuits. They are the path by which scientific understanding becomes more time, fewer symptoms and a greater chance of meaningful benefit for people living with pancreatic cancer.
Today’s research is tomorrow’s therapy